Conference--Standards for Treatment of SLE Patients

会议--SLE患者的治疗标准

• 批准号: 6321632
• 负责人: MATTHEW H. LIANG
• 金额: $ 2.05万
• 依托单位: AMERICAN COLLEGE OF RHEUMATOLOGY
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-06-01 至 2002-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6321632
• 关键词: behavioral /social science research tag; experimental designs; health care policy; meeting /conference /symposium; patient care management; patient care planning; skeletal disorder chemotherapy; systemic lupus erythematosus; travel

DESCRIPTION (Taken from the applicant's abstract): The goal of the efforts proposed in this grant application is to conduct a consensus meeting of an international group of clinician-scientists and clinical trials methodologists to produce standardized response criteria for systemic lupus erythematosus (SLE) trials in the "units" of existing disease activity measures and by selected major organ systems. The field of experimental therapeutics in SLE is on a steep slope of discovery and their evaluation in human subjects will be enhanced if standard end points are used. Standard response criteria will allow meaningful comparisons between trials, promote the use of innovative study designs, and greatly improve the efficiency and shorten the time-line for testing new interventions. This grant will support a meeting of stakeholders to develop consensus response criteria based on data from an international pre-meeting exercise in which over 1000 patient histories were evaluated. Consensus building techniques, such as Delphi and nominal group techniques will be used.

描述（摘自申请人的摘要）：努力的目标 在这个补助金申请中提出的是进行一个共识会议， 国际临床科学家和临床试验方法学家小组 制定系统性红斑狼疮的标准化反应标准 (SLE)在现有疾病活动性衡量标准的“单位”中进行试验， 选择主要器官系统。SLE的实验治疗领域是 在一个陡峭的斜坡上发现和他们的评估在人类受试者将是 如果使用标准端点，则增强。标准反应标准将允许 试验之间有意义的比较，促进创新研究的使用 设计，并大大提高了效率，缩短了时间线， 测试新的干预措施。这笔赠款将支持利益攸关方会议， 根据国际数据制定共识反应标准 评估了1000多名患者的病史。 共识构建技术，如德尔菲和名义组技术， 被利用

项目成果

Response criteria for cutaneous SLE in clinical trials.

临床试验中皮肤系统性红斑狼疮的反应标准。

• 发表时间: 2007
• 期刊: Clinical and experimental rheumatology
• 影响因子: 3.7
• 作者: AdHocCommitteeResponseCriteriaForCutaneousSLE

Methodologic issues in the validation of putative biomarkers and surrogate endpoints in treatment evaluation for systemic lupus erythematosus.

• DOI: 10.2174/187153009787582388
• 发表时间: 2009-03
• 期刊: Endocrine, metabolic & immune disorders drug targets
• 作者: Liang MH;Simard JF;Costenbader K;Dore BT;Ward M;Fortin PR;Illei GG;Manzi S;Mittleman B;Buyon J;Gupta S;Abrahamowicz M
• 通讯作者: Abrahamowicz M